SOURCE: IO NewsWire

IO NewsWire

November 16, 2010 07:30 ET

(OTCBB: BOPH) Posts 57% Increase in Net Income

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire

NEW YORK, NY--(Marketwire - November 16, 2010) - Bohai Pharmaceuticals Group, Inc. (OTCBB: BOPH) announced on Friday their fiscal first quarter earnings, ended September 30th, 2010.

Bohai is engaged in the production, manufacturing and distribution of traditional Chinese Medicine (TCM) in China. The Chinese Government officially supports the use of TCM to enhance the wellness of its population and to treat chronic and acute diseases. The Chinese Government is expected to increase spending in this area to nearly $125 billion in 2010.

Increased Chinese Government regulation has closed nearly a third of pharmaceutical manufacturers in China giving Bohai a larger share of the market and greater credibility as a TCM manufacturer. This should further boost revenues as Bohai continues to expand its operations.

Recently, Bohai was given a 12-month price target of $6.45 a share by Murphy Analytics.

For more information, please visit www.bohaipharma.com/events.html

Other active stocks are Tianyin Pharmaceutical Co (NYSE Amex: TPI) China Sky One Medical (NASDAQ: CSKI) and Midex Gold Corp (PINKSHEETS: MXGD)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information